.After increasing $170 million back in February, metabolic disease-focused BioAge Labs has actually filed to debut on the general public market.The Eli Lilly-partnered biotech want to detail on the Nasdaq under the icon “BIOA,” depending on to documents submitted with the Securities as well as Substitution Compensation. The business has not openly discussed an anticipated financial volume for the offering.The clinical-stage firm touts lead prospect azelaprag, an orally provided little molecule slated to go into phase 2 testing in combo with semaglutide– marketed by Novo Nordisk under brand Wegovy for weight reduction– in the very first one-half of following year. Semaglutide is actually likewise offered as Ozempic as well as Rybelsus through Novo for diabetes.
Apelin receptor agonist azelaprag is created to mix properly with GLP-1 drugs, improving weight reduction while maintaining muscle mass. The investigational drug was actually found to become well-tolerated among 265 individuals across 8 period 1 trials, according to BioAge.Formerly, BioAge achieved the assistance of Lilly to operate a test blending azelaprag along with the Big Pharma’s GLP-1/ GIP receptor agonist tirzepatide, which is industried for diabetes as Mounjaro and Zepbound for effective weight loss. The partners are actually currently conducting a stage 2 test of azelaprag as well as tirzepatide, along with topline end results assumed in the third one-fourth of 2025.The biotech is additionally planning a blood insulin sensitiveness proof-of-concept test examining azelaprag as a monotherapy in the initial one-half of following year to sustain potential indication expansion.
Furthermore, the business organizes to talk to the FDA for permission in the second fifty percent of 2025 to launch human testing for an NLRP3 prevention targeting metabolic health conditions as well as neuroinflammation.BioAge’s foreseed move to the public market follows a mild uptick in considered biotech IPOs from Bicara Rehabs as well as Zenas Biopharma. Zooming out, the current IPO landscape is a “mixed photo,” with high-grade firms still debuting on everyone markets, only in minimized numbers, depending on to PitchBook.